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Abstract 
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease 
(CD), is a chronic inflammatory disorder characterized by intractable inflammation specific to 
the gastrointestinal tract.  The precise etiology of IBD remains unknown.  Recently, 
haplotypes of peptidylarginine deiminase type 4 (PADI4) have been identified as the 
rheumatoid arthritis (RA)-susceptible gene.  PADI4 is located at 1p36, which is one of 
chromosomal loci susceptible for IBD.  Then, we examined whether haplotypes and 
diplotypes of PADI4 are associated with IBD in the Japanese population.  We studied 
haplotypes of PADI4 in 114 patients with UC, 83 patients with CD, and 200 gender-matched 
healthy controls by PCR-restriction fragment length polymorphism.  Frequencies and 
distributions of haplotypes and diplotypes were compared statistically between patients and 
controls by logistic regression analysis.  The frequency of haplotype 1 was significantly 
decreased in patients with UC, compared to that in controls (P = 0.037; odds ratio (OR) = 
0.702).  In contrast, the frequency of haplotype 2 in patients with UC was significantly higher 
than that in controls (P = 0.003; OR = 1.722).  Moreover, of a total of 114 patients with UC, 
15 (13.2%) had a diplotype homozygous for haplotype 2, the frequency being significantly 
higher than in controls (9/200, 4.5%; P = 0.008, OR = 3.215).  Our results indicate that 
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haplotype 1 of PADI4 is associated with non-susceptibility to UC, whereas haplotype 2 is 
susceptible to UC.  Thus, it is likely that PADI4 is one of genetic determinants of UC in the 
Japanese population.  
 
Key words   
Ulcerative colitis, PADI4, haplotype, polymorphism, disease-susceptible gene, Japanese 
population   
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Introduction 
Chronic inflammatory bowel disease (IBD) is a multifactorial disorder that is characterized by 
inflammation specific to the gastrointestinal tract, which results in intestinal malabsorption, 
immune defense abnormalities, and an exaggerated inflammatory response (1,2).  Various 
immune and inflammatory cells, such as lymphocytes, macrophages, and dendritic cells, play 
important roles in the development and progression of IBD (3-5).  In addition, bacterial 
antigens have been implied in the pathological inflammation and may mediate both innate and 
adaptive responses underlying chronic inflammation (6-8).  IBD consists of two main 
subtypes: ulcerative colitis (UC) and Crohn's disease (CD) (1,2).  Although the precise 
etiology of IBD remains unknown, both several environmental factors, such as dietary 
components and microorganisms, and genetic factors may contribute to the occurrence of IBD 
(6-8).  In order to identify the genes underlying the etiology of IBD, genome-wide linkage 
analyses and candidate gene-based association studies have launched and shown possible 
IBD-susceptibility loci at 16q12 (IBD1), 12q13 (IBD2), 6p13 (IBD3), 14q11 (IBD4), 
5q31-q33 (IBD5), 19p13 (IBD6), 1p36 (IBD7), 16q11 (IBD8), 3p21 (IBD9), and other loci 
(8,9). 
 Recently, peptidylarginine deiminase type 4 (PADI4) located at 1p36 is identified as 
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the rheumatoid arthritis (RA)-susceptible gene (10).  RA is involved in autoimmune diseases, 
of which pathoetiology is probably similar to UC in a number of respects with not only 
mechanisms of immune defense abnormalities, such as the elevated production of 
autoantibody (1,2), but also arthritic manifestations, e.g. ankylosing spondylitis and sacroiliitis 
(11).  Although RA complicated by UC is uncommon, recent report has described the 
development of UC in patients with RA (12).  More importantly, PADI4 also lies within the 
IBD-susceptibility locus (IBD7)(8-10).  
Based on the above findings, we hypothesized that PADI4 could play a role in the 
pathogenesis of IBD as well as RA.  Thus, in this study, we have examined whether 
haplotypes and diplotypes of PADI4 are associated with IBD in the Japanese population.   
 
Subjects and Methods   
Subjects   
The study subjects comprised unrelated 114 patients with UC, unrelated 83 patients with CD, 
and 200 gender-matched, unrelated, healthy volunteers as control.  The characteristics of 
subjects are shown in Table 1.  Age at onset is indicated as the mean ± standard deviation 
(SD).  All participants were Japanese who were randomly recruited from 8 general health 
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clinics in the Nagasaki district of Japan.  The study protocol was approved by the Committee 
for Ethical Issues dealing with the Human Genome and Gene Analysis at Nagasaki University, 
and written informed consent was obtained from each participant. 
The diagnosis of IBD was made on the basis of the endoscopic, radiological, 
histological, and clinical criteria provided by the WHO Council for International 
Organizations of Medical Sciences and the International Organization for the Study of 
Inflammatory Bowel Disease (13-15).  Patients with indeterminate colitis and autoimmune 
diseases, such as RA, multiple sclerosis, and systemic lupus erythematosus, were excluded 
from the subjects in this study. 
Patients with UC were classified into subgroups according to age at onset (<40 or 
≥40 years), extension of lesions (proctitis, left-sided colitis, or pancolitis), disease severity 
(mild, moderate, or severe) and activity (active or inactive) (Table 1).  Likewise, patient with 
CD were divided into subgroups according to age at onset (<40 or ≥40 years), localization of 
lesions (ileal, ileocolonic, colonic, or isolated upper disease), behavior of disease (structuring 
and penetrating), and disease severity (mild, moderate, or severe) and activity (active or 
inactive) (Table 1).  The extension and location of UC and CD, disease severity of UC and 
CD, and behavior of CD were stratified in accordance with Montreal classification (16) with 
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slight modification.  A high clinical activity index (CAI>5) for UC (17) and a high Crohn’s 
disease activity index (CDAI>150) (18) were regarded as active phase patients. 
 
The source of polymorphisms studied 
With regard to haplotypes of PADI4 (GenBank accession number: NT_030584), three single 
nucleotide polymorphisms (SNPs), padi4_92, padi4_96, and padi4_102, were selected and 
analyzed, as reported by Caponi et al. (19).  Subsequently, haplotypes were determined to be 
based on combinations of their three SNPs (10), as shown in Tables 2 and 3, because SNPs in 
PADI4 lie in a strong linkage disequilibrium block. 
 
Preparation of genomic DNA 
Genomic DNA was extracted from whole blood of each subject using the DNA Extractor 
WB-Rapid Kit (Wako Pure Chemical Industries, Osaka, Japan), according to the 
manufacturer’s protocol.   
 
Determination of three SNPs in PADI4   
The three SNPs, padi4_92, padi4_96, and padi4_102, were detected by the polymerase chain 
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reaction-based restriction fragment length polymorphism method.  Polymorphic regions were 
amplified by PCR with a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, 
Foster City, CA) using 25 ng of genomic DNA in a 25-µl reaction mixture containing 20 mM 
Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 200 µM dNTPs, using 15 pmol each of 
forward primer: 5’-TCCAGTGGGTGTTTGTTGAA-3’ and reverse primer: 
5’-CATCCTGCAGGGATTAGGAG-3’ for padi4_92; forward primer: 
5’-AAACGACCTGCCCATTC-3’ and reverse primer: 
5’-GGAAATACATAAGCCAAAAT-3’ for padi4_96 (19); forward primer: 
5’-CTGGCCCAGGCACCACCAG-3’ and reverse primer: 
5’-AGGGTTTCGGCAGCTGTGCC-3’ for padi4_102 (19), and 1 U Taq DNA polymerase 
(Invitrogen Co., Carlsbad, CA).  The amplification protocol comprised initial denaturation at 
94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 60°C 
for padi4_92, at 52°C for padi4_96, and at 68°C for padi4_102 for 30 sec, extension at 72°C 
for 30 sec, and final extension at 72°C for 5 min.  The 192-base pair (bp) PCR products for 
padi4_92, 316-bp PCR products for padi4_96, and 400-bp PCR products for padi4_102 were 
digested at 37°C overnight by restriction enzymes, Msp I (Takara Bio, Shiga, Japan), Hae III 
(Toyobo, Osaka, Japan), and Rsa I (Toyobo), respectively (19).  The digests were subjected 
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to electrophoresis on a 6% polyacrylamide gel (Nacalai Tesque, Kyoto, Japan) for padi4_92, 
or on a 2% agarose gel (Nacalai Tesque) for padi4_96 and padi4_102, then stained with 
ethidium bromide (Nacalai Tesque) and visualized with UV transilluminator (Alpha Innotech, 
San Leandro, CA).   
 
Statistical analysis   
Gender and age values between patients and control subjects were evaluated by chi-square test 
and unpaired Student’s t-test, respectively.  Expected allele frequencies were calculated from 
respective single allele frequencies according to the Hardy-Weinberg equilibrium.  The 
observed and expected allele frequencies were compared by chi-square test with Yates’ 
correction using SNP Alyze 6.01 standard (Dynacom Inc., Yokohama, Japan).  The 
frequencies and distributions of haplotype and diplotype were compared between patients and 
control subjects by logistic regression analysis.  SPSS 15.0 program package (SPSS Japan 
Inc., Tokyo, Japan) was used for all statistical analyses including calculation of odds ratio 




Results and Discussion   
The distributions of genotypes of each SNP on PADI4 in each group corresponded to the 
Hardy-Weinberg equilibrium (Data not shown).  We identified 7 haplotypes composed of 3 
SNPs among the subjects in this study (Tables 2 and 3).  However, the rare frequent 
haplotypes, Hap 5, Hap 6, and Hap 7, were excluded in Tables 2 and 3.  The frequencies and 
distributions of haplotypes in our study population corresponded to that in previous studies on 
association with RA in other Japanese populations (10,20).  These results imply that the 
population studied had a homogeneous genetic background. 
 The frequency of haplotype 1 was significantly decreased in patients with UC, 
compared to that in control subjects (P = 0.037; OR = 0.702) (Table 2).  While, the frequency 
of haplotype 2 was significantly increased in patients with UC, compared to that in control 
subjects (P = 0.003; OR = 1.722) (Table 2).  However, there were no differences in the 
frequency of haplotypes between patients with CD and control subjects (Tables 3).  
With regard to genotype, referred to as diplotype, of PADI4, 12 diplotypes composed 
of 7 haplotypes were identified (Tables 4 and 5).  However, the rare frequent diplotypes, Hap 
2/Hap 6, Hap 3/Hap 3, Hap 3/Hap 3, Hap 3/Hap 6, and Hap 4/Hap 4, were excluded in Tables 
4 and 5.  Of a total of 114 patients with UC, 15 (13.2%) had a diplotype homozygous for 
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haplotype 2 (Hap 2/2 in Table 4), the frequency being significantly higher than in control 
subjects (9/200, 4.5%; P = 0.008, OR = 3.215) (Table 4).  In contrast, although statistical 
analysis did not show to be significant, it was a tendency that the frequency of UC patients 
possessing haplotype 1 homozygosity (Hap 1/1 in Table 4) was lower than that of control 
subjects (34/114, 29.8% vs. 81/200, 40.5%; P = 0.060, OR = 0.624)(Table 4).  Thus, this is 
the first report on the association of PADI4 haplotypes as well as diplotypes with IBD. 
Moreover, the frequency of another diplotype heterozygous for haplotype 1 and 
haplotype 4 (Hap 1/4 in Table 5) in CD was significantly lower than that in Control (3/83, 
3.6% vs. 23/200, 11.5%; P = 0.048, OR = 0.289) (Table 5).  With respect to CD, it remains to 
be confirmed why the diplotype, Hap 1/Hap 4 is associated with non-susceptibility to CD.  It 
is one of the possibilities that these CD patients might become complicated by UC in the 
future, since pathoetiology of certain CD patients would be closely similar to that of UC 
patients in spite of unknown molecular mechanisms (21).  
Again, we analyzed the distributions of haplotypes and diplotypes of PADI4 among 
UC and CD subgroups (Tables 6 and 7).  There were no significant differences in frequencies 
of the haplotypes and diplotypes among the subgroups of each IBD subtype. 
 PDAI enzymes post-translationally catalyze the conversion of arginine residues into 
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citrulline (22).  Citrullinated epitopes are involved in a peptide linkage and are the most 
specific targets of RA-related autoantibodies (23-25).  In fact, anti-cyclic citrullinated 
peptides (anti-CCPs) antibody has been specifically observed in the sera of RA patients and 
their presence is a useful diagnostic marker for RA (26).  Suzuki and colleagues have 
identified that a haplotype (haplotype 2) of PADI4 on IBD locus at 1p36 was closely 
associated with susceptibility to RA (10).  PADI4 mRNA from the susceptible haplotype 2 
was significantly more stable than that from non-susceptible alleles (10), linking to more 
enhanced production of the citrullinated peptides including CCPs.  With respect to a possible 
mechanism for the extra cellular immune sampling for PADIs of a cytoplasmic enzymatic 
activity, Ireland et al. demonstrated that when mice were immunized with hen egg-white 
lysozyme (HEL), a unique cohort of T cells selectively responded to its citrullinated epitopes.  
That is, dendritic cells and macrophages sampled the extra cellular antigen (HEL), presented 
the citrullinated ones of HEL bound to the MHC molecule and stimulated 
modification-specific T cells (27).  Thus, the citrullinated proteins are antigenic and 
presentation of the citrullinated peptides-MHC complex is a feature of immune response to the 
protein antigens.  It has been reported that PDAIs are exclusively expressed in synovial 
tissues, neutrophils and mononuclear cells infiltrating into arthritic joints, where the 
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citrullinated peptides can be overproduced, especially in the subjects with haplotype 2 of 
PADI4 (25, 29), and, then processed into the CCP-MHC complex in such antigen-presenting 
cells and may serve as autoanti-antigens.  Although serologic examinations including 
anti-CCPs antibody and anti-neutrophil cytoplasmic antibody (ANCA) were not performed in 
this study and ANCA antibody is associated with UC (30), there are no reports on a correlation 
between circulating anti-CCPs antibody and IBD.  Furthermore, it is well known that 
autoimmune phenomena are involved in the pathogenesis of IBD (1,2,31).  For example, 
serum and mucosal autoantibodies against intestinal epithelial cells, human tropomyosin 
fraction V, and human neutrophil cytoplasm are present in UC (30, 31); this implies that 
PADI4 haplotypes may be associated with the onset and/or development of UC through an 
autoimmune reaction against citrullinated self-peptides. 
The present study has several limitations.  Enzyme activities of PADI4 and other 
PADI4 isoforms, serologic examinations including anti-CCPs and ANCA antibodies, and 
polymorphisms of other PADI4 isoforms should be elucidated.  The number of subjects was 
relatively small.  Therefore, the association observed here needs to be confirmed in a larger 
sample of Japanese patients, as well as in other populations.  With regard to other populations, 
Asian studies in Japan and Korea (10,20,32) have shown a close correlation between the 
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PADI4 haplotypes and RA, but not in Caucasian RA patients (33-35).  Inversely, mutations 
of the caspase activating recruitment domain 15/nucleotide oligomerization domain 2 gene 
(CARD15/NOD2) at 16q12 (IBD1 locus) were associated with Crohn’s disease in the 
Caucasian, but not in the Japanese (36-39).  These findings may be due to different genetic 
background between the races.  Even if there is a difference in the molecular mechanism of 
the pathogenesis of UC between Caucasian and Japanese patients, our results suggest that 
PADI4 may be one of genetic determinants of UC in the Japanese population, or that another 
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Tables 





Number 114 83 200 
Age (yrs) 44.2  16.7* 34.3  12.5 32.5  11.2 
Age range (yrs) 14-83 17-75 20-60 
Male/female (%) 59/55 (51.7/48.3) 50/33 (60.2/39.8) 125/75 (62.5/37.5) 
Age at onset    
  <40 y 39** 11  
  ≥40 y 75 72  
Extent of UC    
  Proctitis 14   
  Left sided UC 43   
  Pancolitis 57   
Location of CD    
  Ileal  16  
  Colonic  11  
  Ileocolonic  55  
  Upper  1  
Disease severity    
  Mild 51 17  
  Moderate 38 45  
  Severe 21 9  
  Unknown 4 12  
Disease activity    
  Active 63 54  
  Inactive 48 17  
  Unknown 3 12  
Behavior of CD***    
  Stricturing  44  
  Penetrating  40  
  Perianal diseases  36  
P<0.01, as compared with controls* and CD**, ***, number of the affected patients. 
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Table 2: The distributions and association of haplotypes of PDAI4 between UC patients 
and control subjects 
Haplotype 
(Ref 10) 
SNP ID (padi4_X)  Number (%) of haplotypes in* Haplotype comparison* 
92 96 102  UC Control OR (95%CI) P 
Hap 1 C T C  126 (55.3) 255 (63.8) 0.702 (0.504-0.978) 0.037 
Hap 2 G C C  76 (33.3) 90 (22.5) 1.722 (1.199-2.473) 0.003 
Hap 3 G C T  14 (6.2) 22 (5.5) 1.124 (0.563-2.243) 0.740 
Hap 4 G T C  11 (4.8) 30 (7.5) 0.625 (0.307-1.273) 0.195 
Others       1 (0.4) 3 (0.7) — — 
Total number of haplotypes  228 400   




Table 3: The distributions and association of haplotypes of PDAI4 between CD patients 
and control subjects 
Haplotype 
 (Ref 10) 
SNP ID (padi4_X)  Number (%) of haplotypes in Haplotype comparison* 
92 96 102  CD Control OR (95% CI) P 
Hap 1 C T C  100 (60.3) 255 (63.8) 0.862 (0.594-1.249) 0.432 
Hap 2 G C C  47 (28.3) 90 (22.5) 1.360 (0.594-1.249) 0.142 
Hap 3 G C T  10 (6.0) 22 (5.5) 1.101 (0.510-2.380) 0.806 
Hap 4 G T C  8 (4.8) 30 (7.5) 0.624 (0.280-1.392) 0.250 
Others     1 (0.6) 3 (0.7) — — 
Total number of haplotypes  166 400   




Table 4: The distributions and association of diplotypes of PDAI4 between UC patients 
and control subjects 
Diplotype 
Number (%) of diplotypes in diplotype comparison* 
UC Control OR (95% CI) P 
Hap 1/1 34 (29.8) 81 (40.5) 0.624 (0.382-1.020) 0.060 
Hap 1/2 41 (36.0) 57 (28.5) 1.409 (0.863-2.301) 0.171 
Hap 1/3 8 (7.0) 13 (6.5) 1.086 (0.436-2.704) 0.860 
Hap 1/4 9 (7.9) 23 (11.5) 0.660 (0.294-1.479) 0.313 
Hap 2/2 15 (13.2) 9 (4.5) 3.215 (1.359-7.609) 0.008 
Hap 2/3 3 (2.6) 7 (3.5) 0.745 (0.189-2.940) 0.674 
Hap 2/4 2 (1.7) 5 (2.5) 0.696 (0.133-3.649) 0.669 
Others 2 (1.7) 5 (2.5) — — 
Total number 114 200   
*Each diplotype was compared with other diplotypes combined by logistic regression analysis. 
Czin 4 
 4 
Table 5: The distributions and association of diplotypes of PDAI4 between CD patients 
and control subjects 
Diplotype 
Number (%) of diplotypes in diplotype comparison* 
CD Control OR (95% CI) P 
Hap 1/1 33 (39.8) 81 (40.5) 0.970 (0.575-1.635) 0.908 
Hap 1/2 26 (31.3) 57 (28.5) 1.144 (0.656-1.996) 0.635 
Hap 1/3 5 (6.0) 13 (6.5) 0.922 (0.318-2.674) 0.881 
Hap 1/4 3 (3.6) 23 (11.5) 0.289 (0.084-0.989) 0.048 
Hap 2/2 7 (8.4) 9 (4.5) 1.955 (0.703-5.436) 0.199 
Hap 2/3 4 (4.8) 7 (3.5) 1.396 (0.398-4.902) 0.603 
Hap 2/4 3 (3.6) 5 (2.5) 1.463 (0.341-6.265) 0.609 
Others 2 (2.4) 5 (2.5) — — 
Total number 83 200   
*Each diplotype was compared with other diplotypes combined by logistic regression analysis. 
Czin 5 
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Table 6: The distributions of haplotypes of PDAI4 with respect to subtypes of UC and 
CD patients. 
    Number (%) of haplotypes in 
    Hap1 Hap2 Hap3 Hap4 Others Total 
UC 
Extent   
  Proctitis 16 (57.1) 9 (32.1) 2 (7.1) 1 (3.6) 0 (0) 28
  Left sided UC 47 (54.7) 30 (34.9) 2 (2.3) 7 (8.1) 0 (0) 86
  Pancolitis 63 (55.3) 37 (32.5) 10 (8.8) 3 (2.6) 1 (0.9) 114
Disease severity   
  Mild 56 (54.9) 38 (37.3) 4 (3.9) 4 (3.9) 0 (0) 102
  Moderate 39 (51.3) 24 (31.6) 9 (11.8) 4 (5.3) 0 (0) 76
  Severe 24 (57.1) 13 (31.0) 1 (2.4) 3 (7.1) 1 (2.4) 42
  Unknown 7 (87.5) 1 (12.5) 0 (0) 0 (0) 0 (0) 8
Disease activity   
  Active 70 (55.6) 41 (32.5) 6 (4.8) 8 (6.3) 1 (0.8) 126
  Inactive 51 (53.1) 34 (35.4) 8 (8.3) 3 (3.1) 0 (0) 96
 Unknown 5 (83.3) 1 (16.7) 0 (0) 0 (0) 0 (0) 6
CD 
Location   
  Ileal 17 (53.1) 11 (34.4) 0 (0) 4 (12.5) 0 (0) 32
  Colic 13 (59.1) 7 (31.8) 1 (4.5) 1 (4.5) 0 (0) 22
  Ileocolic 69 (62.7) 29 (26.4) 8 (7.3) 3 (2.7) 1 (0.9) 110
  Upper 1 (50.0) 0 (0) 1 (50.0) 0 (0) 0 (0) 2
Disease severity   
  Mild 16 (47.1) 13 (38.2) 1 (2.9) 4 (11.8) 0 (0) 34
  Moderate 54 (60.0) 26 (28.9) 7 (7.8) 3 (3.3) 0 (0) 90
  Severe 13 (72.2) 2 (11.1) 2 (11.1) 0 (0) 1 (5.6) 18
  Unknown 17 (70.8) 6 (25.0) 0 (0) 1 (4.2) 0 (0) 24
Disease activity   
  Active 67 (62.0) 28 (25.9) 9 (8.3) 3 (2.8) 1 (0.9) 108
  Inactive 16 (47.1) 13 (38.2) 1 (2.9) 4 (11.8) 0 (0) 34
 Unknown 17 (70.8) 6 (25.0) 0 (0) 1 (4.2) 0 (0) 24
Stricturing   
  Present 55 (62.5) 23 (26.1) 5 (5.7) 4 (4.5) 1 (1.1) 88
  Absent 45 (57.7) 24 (30.8) 5 (6.4) 4 (5.1) 0 (0) 78
Penetrating   
  Present 49 (61.3) 23 (28.8) 5 (6.3) 2 (2.5) 1 (1.3) 80
  Absent 51 (59.3) 24 (27.9) 5 (5.8) 6 (7.0) 0 (0) 86
Perianal diseases   
  Present 43 (59.7) 19 (26.4) 6 (8.3) 4 (5.6) 0 (0) 72
  Absent 57 (62.0) 26 (28.3) 4 (4.3) 4 (4.3) 1 (1.1) 92
  Unknown 0 (0.0) 2 (100.0) 0 (0) 0 (0) 0 (0) 2
Table 7: The distributions of diplotypes of PDAI4 with respect to subtypes of UC and CD patients. 
    Number (%) of diplotypes in
    Hap 1/1 Hap 1/2 Hap 1/3 Hap 1/4 Hap 2/2 Hap 2/3 Hap 2/4 Others Total 
UC 
Extent      
  Proctitis 6 (42.9) 2 (14.3) 2 (14.3) 0 (0) 3 (21.4) 0 (0) 1 (7.1) 0 (0) 14 
  Left sided UC 11 (25.6) 18 (41.9) 1 (2.3) 6 (14.0) 5 (11.6) 1 (2.3) 1 (2.3) 0 (0) 43 
  Pancolitis 17 (29.8) 21 (36.8) 5 (8.8) 3 (5.3) 7 (12.3) 2 (3.5) 0 (0) 2 (3.5) 57 
Disease severity          
  Mild 17 (33.3) 16 (31.4) 3 (5.9) 3 (5.9) 10 (19.6) 1 (2.0) 1 (2.0) 0 (0) 51 
  Moderate 8 (21.5) 15 (39.5) 5 (13.2) 3 (7.9) 3 (7.9) 2 (5.3) 1 (2.6) 1 (2.6) 38 
  Severe 6 (28.6) 9 (42.9) 0 (0) 3 (14.3) 2 (9.5) 0 (0) 0 (0) 1 (4.8) 21 
  Unknown 3 (75.0) 1 (25.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 
Disease activity          
  Active 19 (30.2) 20 (31.7) 5 (7.9) 7 (11.1) 10 (15.9) 0 (0) 1 (1.6) 1 (1.6) 63 
  Inactive 13 (27.1) 20 (41.7) 3 (6.3) 2 (4.2) 5 (10.4) 3 (6.3) 1 (2.1) 1 (2.1) 48 
 Unknown 2 (66.7) 1 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 
CD 
Location      
  Ileal 5 (31.3) 7 (43.8) 0 (0) 0 (0) 1 (6.3) 0 (0) 2 (12.5) 1 (6.3) 16 
  Colic 4 (36.4) 3 (27.3) 1 (9.1) 1 (9.1) 2 (18.2) 0 (0) 0 (0) 0 (0) 11 
  Ileocolic 24 (43.6) 16 (29.1) 3 (5.5) 2 (3.6) 4 (7.3) 4 (7.3) 1 (1.8) 1 (1.8) 55 
  Upper 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 
Disease severity          
  Mild 2 (11.8) 9 (52.9) 1 (5.9) 2 (11.8) 2 (11.8) 0 (0) 0 (0) 1 (5.9) 17 
  Moderate 19 (42.2) 12 (26.7) 3 (6.7) 1 (2.2) 4 (8.9) 4 (8.9) 2 (4.4) 0 (0) 45 
  Severe 5 (55.6) 2 (22.2) 1 (11.1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (11.1) 9 
  Unknown 7 (58.3) 3 (25.0) 0 (0) 0 (0) 1 (8.3) 0 (0) 1 (8.3) 0 (0) 12 
Disease activity          
  Active 24 (44.4) 14 (25.9) 4 (7.4) 1 (1.9) 4 (7.4) 4 (7.4) 2 (3.7) 1 (1.9) 54 
  Inactive 2 (11.8) 9 (52.9) 1 (5.9) 2 (11.8) 2 (11.8) 0 (0) 0 (0) 1 (5.9) 17 
 Unknown 7 (58.3) 3 (25.0) 0 (0) 0 (0) 1 (8.3) 0 (0) 1 (8.3) 0 (0) 12 
Stricturing          
  Present 19 (43.2) 13 (29.5) 2 (4.5) 2 (4.5) 3 (6.8) 2 (4.5) 2 (4.5) 1 (2.3) 44 
  Absent 14 (35.9) 13 (33.3) 3 (7.7) 1 (2.6) 4 (10.3) 2 (5.1) 1 (2.6) 1 (2.6) 39 
Penetrating          
  Present 16 (40.0) 13 (32.5) 2 (5.0) 2 (5.0) 4 (10.0) 2 (5.0) 0 (0) 1 (2.5) 40 
  Absent 17 (39.5) 13 (30.2) 3 (7.0) 1 (2.3) 3 (7.0) 2 (4.7) 3 (7.0) 1 (2.3) 43 
Perianal diseases          
  Present 15 (41.7) 9 (25.0) 3 (8.3) 1 (2.8) 3 (8.3) 3 (8.3) 1 (2.8) 1 (2.8) 36 
  Absent 18 (39.1) 17 (37.0) 2 (4.3) 2 (4.3) 3 (6.5) 1 (2.2) 2 (4.3) 1 (2.2) 46 
  Unknown 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 1 
 
